Table 3 Antibiotic resistance pattern of the prevalent gram-negative pathogens isolated from patients admitted in ICU, Ain Shams University Hospitals, Egypt, March 2018-February 2019
Antibiotic | Resistant isolates, n (%) | Total , n/N(%) (N = 736) | p value | |||||
|---|---|---|---|---|---|---|---|---|
Acinetobacter spp. (n = 128) | Klebsiella spp (n = 288) | E.coli spp. (n = 172) | Pseudomonas spp. (n = 114 | Proteus spp. (n = 23 | Enterobacter spp. (n = 11) | |||
Amikacin | 113 (88.28) | 208 (72.22) | 21 (12.21) | 76 (66.66) | 6 (26.08) | 3 (27.27) | 427/736 (58.01) | p < 0.001* |
Amoxicillin/clavulanate | **NA | 245 (85.06) | 124 (72.09) | **NA | 12 (52.17) | 3 (27.27) | 384/494 (77.73) | p < 0.001* |
Ampicillin/sulbactam | 110 (85.93) | 277 (96.18) | 155 (90.11) | **NA | 14 (60.08) | 4(36.36) | 560/622 (90.03) | p < 0.001* |
Cefepime | 110 (85.93) | 276 (96.83) | 157 (91.27) | 91 (79.82) | 7 (30.43) | 8 (72.72) | 649/736 (88.17) | p < 0.001* |
Cefotaxime | 124 (96.87) | 285 (98.95) | 152 (88.37) | **NA | 12 (52.17) | 10 (90.90) | 583/622 (93.72) | p < 0.001* |
Cefoxitin | **NA | 248 (86.11) | 92 (53.48) | **NA | 7 (30.43) | 10 (90.90) | 357/494 (72.26) | p < 0.001* |
Cefpodoxime | **NA | 282 (97.91) | 160 (93.02) | **NA | 10 (43.47) | 9 (81.81) | 461/494 (93.31) | p < 0.001* |
Ceftazidime | 115 (89.84) | 279 (96.87) | 156 (90.69) | 92 (80.70) | 8 (34.78) | 10 (90.90) | 660/736 (89.67) | p < 0.001* |
Ceftriaxone | 127 (99.21) | 285 (98.95) | 152 (88.37) | **NA | 12 (52.17) | 10 (90.90) | 586/622 (94.21) | p < 0.001* |
Ciprofloxacin | 111 (86.71) | 258 (89.58) | 122 (70.93) | 91 (79.82) | 13 (56.52) | 6 (54.54) | 601/736 (81.65) | p < 0.001* |
Doxycycline | 85 (66.41) | 235 (81.59) | 123 (71.51) | **NA | 19 (82.60) | 9 (81.81) | 471/622 (75.72) | 0.008* |
Gentamicin | 97 (75.78) | 204 (70.83) | 66 (38.37) | 81 (71.05) | 10 (43.47) | 5 (45.45) | 463/736 (62.90) | p < 0.001* |
Imipenem | 101 (78.91) | 225 (78.12) | 32 (18.60) | 75 (65.78) | 4 (17.39) | 3 (27.27) | 440/736 (59.78) | p < 0.001* |
Levofloxacin | 109 (85.15) | 231 (80.21) | 119 (69.18) | 87 (76.31) | 14 (60.86) | 5 (45.45) | 565/736 (76.76) | 0.001* |
Meropenem | 103 (80.46) | 228 (79.16) | 34 (19.76) | 81 (71.05) | 4 (17.39) | 5 (45.45) | 455/736 (61.82) | p < 0.001* |
Piperacillin/tazobactam | 107 (83.59) | 250 (86.81) | 95 (55.23) | 80 (70.17) | 5 (21.73) | 10 (90.90) | 547/736 (74.32) | p < 0.001* |
Tetracycline | 114 (89.06) | 240 (83.33) | 130 (75.58) | **NA | 17 (73.91) | 3 (27.27) | 504/622 (81.02) | p < 0.001* |
Tobramycin | 90 (70.31) | 234 (81.25) | 106 (61.62) | 92 (80.70) | 6 (26.08) | 7 (63.63) | 535/736 (72.69) | p < 0.001* |
Trimethoprim/sulfamethoxazole | 87 (67.96) | 241 (83.68) | 137 (79.65) | **NA | 16 (69.56) | 3 (27.27) | 484/622 (77.81) | p < 0.001* |
Colistin | 0 (0) | **NA | **NA | 0 (0) | **NA | **NA | **NA | – |
Nitrofurantoin | NA | 77 (76.23) | 32 (30.18) | **NA | **NA | 0 (0) | 109/209 (52.15) | p < 0.001* |
No of urine samples | 33 | 101 | 106 | 49 | 5 | 2 | 296 | |